Mankind Pharma Limited
Bookbuilding IPO · NSE, BSE
- Price band
- ₹1026 - ₹1080
- Lot size
- 13 shares
- Issue amount
- ₹4,326.36 cr
- Total subscription
- 15.32×
- Opens
- 25 Apr 2023
- Closes
- 27 Apr 2023
- Allotment
- 4 May 2023
- Listing
- 9 May 2023
Offer at a glance
Issue overview
- Issue size
- 4,00,58,844 shares
- Face value
- ₹1 Per Share
- Minimum investment
- ₹13,338
- Fresh issue
- ₹0 cr
- Offer for sale
- ₹4,326.36 cr
- Registrar
- KFin Technologies Limited
- Listing exchange
- NSE, BSE
- Maximum investment
- ₹14,040
- Issue type
- Bookbuilding IPO
- Shares before issue
- 40,05,88,440
- Shares after issue
- 40,05,88,440
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 1 | 13 | ₹14,040 |
| sHNI | 15 | 195 | ₹2,10,600 |
| bHNI | 72 | 936 | ₹10,10,880 |
Share reservation
Subscription & GMP
Subscription by category
Missing multiples are calculated from bids and offered shares when available.
GMP history
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 822.01 | 42,534.08 |
| RETAIL | 1,438.51 | 1,388.45 |
| HNIs 2+ | 205.5 | 304.8 |
| HNIs 10+ | 411 | 2,160.05 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Values |
|---|---|
| 33.20 | 33.2 |
| ROE | 27.6 |
| ROCE | 26.1 |
| 27.70 | 27.7 |
| 33.20 | 32.5 |
| 0 | 0 |
Values and labels as reported in the issue data.
Company information
Company profile
Incorporated in 1991, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products across a wide range of acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. The company offers over 36 brands such as Manforce, Moxikind-CV, Amlokind-AT, Prega News, and Gudcef, supported by one of the largest distribution networks of medical representatives in India, with over 80% of doctors prescribing its formulations. Ranked 4th in domestic sales in FY2022, Mankind Pharma has received numerous awards, including The Best of Bharat Awards 2022, National Awards for Manufacturing Competitiveness Silver Medal 2021, and recognition for Best Design in Healthcare and performance management excellence.
Promoters
Ramesh Juneja
Rajeev Juneja
Sheetal Arora
Ramesh Juneja Family Trust
Rajeev Juneja Family Trust
Prem Sheetal Family Trust
Registrar & documents
Lead manager
Kotak Mahindra Capital Company, Axis Capital Limited, IIFL Capital Services Limited, Jefferies India Private Limited, J.P. Morgan India Private Limited
Registrar & contacts
KFin Technologies Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
208, Okhla Industrial Estate Phase-III, New Delhi 110020
+91 11 4684 6700
[email protected]Company website ↗Understanding MANKIND IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.